Abiopharma

🔍 Nabiey Romin (Executive)

Company: GoodRx Holdings, Inc. (GDRX)

Report Date: 2025-09-08

Detailed Transactions and Holdings:

• Acquired 10,201 shares of Class A Common Stock (Direct)
  Date: 2025-09-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 147,493.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,650 shares of Class A Common Stock at $4.0 per share (Direct)
  Date: 2025-09-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 143,843.00 | transaction_form_type: 4
• Acquired 2,232 shares of Class A Common Stock (Direct)
  Date: 2025-09-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 146,075.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 799 shares of Class A Common Stock at $4.0 per share (Direct)
  Date: 2025-09-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 145,276.00 | transaction_form_type: 4
• Sold 10,201 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,803.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 2,232 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,323.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
• F2: The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.
• F3: The restricted stock unit award will vest as to 6.25% of the underlying shares on June 8, 2024 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.